Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 29Paclitaxel 7Magnetic Resonance Spectroscopy 7Cisplatin 7Pemetrexed 6Docetaxel 6Carboplatin 6Standard of Care 5Radiotherapy 5Nivolumab 5Drug Therapy 5Specimen Handling 4Gemcitabine 4Cetuximab 4Blood Specimen Collection 4epacadostat 3X-Rays 3Surveys and Questionnaires 3Practice Guidelines as Topic 3Oncolytic Virotherapy 3Nicotine 3Fluorouracil 3Filgrastim 3Cyclophosphamide 3Bupropion 3Bortezomib 3Biopsy 3spartalizumab 2selpercatinib 2sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × CIMAvax EGF × Head & Neck × Clear all
NCT02955290 2025-11-10

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
51 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡